Stablecoin Development Corporation · AMEX:SDEV

Stablecoin Development — NovaBay Pharmaceuticals — Investor Presentation (June 2017)

29 slides from Stablecoin Development's investor presentation, June 2017

  1. Slide 1: Harnessing the Anti-Infective Power of White Blood Cell Chemistry

    Harnessing the Anti-Infective Power of White Blood Cell Chemistry to Address Ophthalmic Diseases Afflicting 41 Million Americans NYSE MKT: NBY www.novabay.com June 2017

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements, within the meaning of applicable U.S. securities laws, which statements can, in some cases, be identified with terms such as “project,” “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,”

  3. Slide 3: Summary Highlights

    Summary Highlights • Specialty Pharma – Commercial stage; Sold by Prescription • Company founded to address antibiotic resistance crisis • Turnaround in 2016 • 2016 sales tripled over 2015 • Cash Flow breakeven achieved for month of Dec’16 • Strong experienced management team • High-growth in large

  4. Slide 4: Leading the NovaBay Commercial Transition

    Leading the NovaBay Commercial Transition Mark Sieczkarek – Chairman, CEO & President • 40 years in the Life Sciences—Large and Small Companies • Pharmaceutical, Consumer; Diagnostics and Medical Devices; Finance, Sales & Marketing; Manufacturing; Mergers and Acquisitions; General Management • Brist

  5. Slide 5: The Foundation of NovaBay Technology

    The Foundation of NovaBay Technology Commercializing Products That Mimic the Anti-Microbial Power of Neutrophils Bacteria White Blood Cell Red blood cells Neutrophil NovaBay’s Breakthrough: Neutrox® • Proprietary formulation, pure hypochlorous acid (HOCl) • Identical to molecule produced by neutroph

  6. Slide 6: Avenova Package Insert Lists Confirmed Time-Kills and Broad Spectrum Activity

    Avenova Package Insert Lists Confirmed Time-Kills and Broad Spectrum Activity Related to Most Common Eye Infections 7

  7. Slide 7: Advantages

    Advantages Does not ✓ generate Resistance ✓Mechanical ✓ Bacterial removal debridement ✓ ✓Anti-toxin Anti-biofilm activity 7

  8. Slide 8: What is Blepharitis?

    What is Blepharitis? Blepharon, Greek “eyelid” + itis – inflammatory disease • Caused by constant high bacterial load around eyes • Condition is chronic and incurable • Signs and symptoms • Itchy, sore, red eyelids; eyelids stick together; burning, gritty sensation • High incidence • 37% of patients

  9. Slide 9: 2016 ARVO Presentation

    2016 ARVO Presentation Clinical study confirmed Avenova’s Rapid Time-Kill and Broad Antimicrobial Effects ARVO, May, 2016 9

  10. Slide 10: Addressing 41 Million Potential Patients in U.S.

    Addressing 41 Million Potential Patients in U.S. Blepharitis 24M Dry eye 6M Contact lens Surgery - intolerance Retinal Surgery - Cataract 4M injections Lasik 3M 3M 1M Dry Eye Is the only market segment addressed by Restasis® and Xiidra® (Effects of these two drugs may be enhanced when used in combin

  11. Slide 11: Commercial Targets

    ams Commercial Targets Avenova’ N@®vaBay PHARMA 11

  12. Slide 12: Market Coverage

    Market Coverage Northeast (11): 50 Direct Medical Reps in Key Metro Areas Albany, Brooklyn, Manhattan, Nassau County, White Plains, Cherry Hill, Boston, Hartford, Patterson, Wash, DC, Philadelphia Midwestern (10): Chicago-No, Chicago-So, Detroit, St. Louis, Buffalo, St. Paul, Kansas City, KS, Clevel

  13. Slide 13: Reimbursement: Insurance Coverage Continues to Grow

    Reimbursement: Insurance Coverage Continues to Grow 13 13

  14. Slide 14: Extensive Media Campaigns Targeting Dry Eye Underway

    Extensive Media Campaigns Targeting Dry Eye Underway Defensive Ads for Restasis® Xiidra® Launch Promotions (57,000 Rx/Week) (17,000 Rx/Week) 14

  15. Slide 15: How Products Compare in the Management of MGD Dry Eye

    How Products Compare in the Management of MGD Dry Eye U.S. Market of 30 Million Patients Avenova Restasis® Xiidra® Benefits Launch Date Q4, 2014 2003 Q4, 2016 - Blocks Cytokines - Kills Bacteria - Penetrates Biofilm - Blocks Bacterial Toxins - Blocks Lipase None Burning, redness, discharge, Stinging

  16. Slide 16: Contains Only 2 Ingredients: Pure Hypochlorous Acid and Saline

    contains only 2 Ingredients = 1. Pure Hypochlorous Acid + 2. Saline Oasis OCuSoft SteriLid Lid and Lash LIDCLENZ VisiCleanse Eye Scrub Hypochlor Acuicyn Water , PEG-80 Water , PEG 80 , Water, Poloxamer, Non-foaming Water, Water USP HOCl 60% HOCl 60% Sorbitan Laurate Sorbitan Laurate Polyethylene, pH

  17. Slide 17: Avenova Beneficial at All Severity Levels of Dry Eye

    Avenova Beneficial at All Severity Levels of Dry Eye Treatment Recommendations by Severity Levels 18

  18. Slide 18: Direct Buy & Bill Sales and Prescriptions Sales

    3,905 3,620 882 3,088 842 Direct Buy & Bill Sales 23% 2,578 Prescriptions Sales 1,003 914 1,580 1,366 3,023 2,778 77% 1,118 806 70% 1,115 2,085 813 1,664 797 465 684 425 30% 465 553 321 40 122 1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16 1Q17 18

  19. Slide 19: Weekly Trend of Lid Disease Rx Products

    Weekly Trend of Lid Disease Rx Products October, 2016 to May 12, 2017 Only Avenova Is Now Exceeding Dec’16 Rx Highs

  20. Slide 20: Multipronged Commercial Strategy

    Multipronged Commercial Strategy • Focus on Rx marketing strategy • Ophthalmology channel has greatest growth potential • Avenova pricing model recognizes full value/benefits • Strategy supported by insurance coverage exceeding 90% • Accessible in 90+% of retail pharmacies through distribution agree

  21. Slide 21: Ophthalmic Advisory Board

    Ophthalmic Advisory Board Dr. Eric Donnenfeld Past president of Ocular Microbiology and Immunology Group and serves on the Board of Directors of American Society of Cataract and Refractive Surgery. Dr. Donnenfeld has published over 175 journal articles, and >20 book chapters and books. Dr. Richard L

  22. Slide 22: Optometry Advisory Board

    Optometry Advisory Board Dr. Arthur Epstein Director of Dry Eye – Ocular Surface Disease Center and Director of Clinical Research at Phoenix Eye Care; heads practice’s Dry-Eye – Ocular Surface Disease Center and serves as Director of Clinical Research. Internationally recognized expert in complex co

  23. Slide 23: Advertising

    Advertising Placements in Top Trade Journals Collateral Marketing Materials 23

  24. Slide 24: Interactive Website

    Interactive Website Find a Physician Find a Pharmacy 24

  25. Slide 25: Success Stories Written by NovaBay KOLs

    Success Stories Written by NovaBay KOLs 25

  26. Slide 26: Success Stories Written by NovaBay KOLs

    Success Stories Written by NovaBay KOLs Avenova With Neutrox Is ‘Breakthrough’ in Fight Against New Therapy Introduced for Chronic Dry Eye Contact Lens Intolerance 26

  27. Slide 27: Success Stories Written by NovaBay KOLs

    Success Stories Written by NovaBay KOLs Dry Eye: A Growing Problem in an Aging Population New Treatments for Contact Lens Intolerance On The Rise 27

  28. Slide 28: Financial Overview

    Financial Overview Million Market Cap (6/2/17) $36 Cash (3/31/17) $7.4 Debt $0 Shares Outstanding (3/31/17) 15.3 (Excludes: Stock Options of 2.2M; Warrants of 0.5M) 2017 Guidance – Total Annual Sales $19 2017 Guidance – Annual Net Cash Burn ($3) 28

  29. Slide 29: In Summary…

    In Summary… • Significant commercial opportunity with Avenova • Proprietary formulation with proven antimicrobial properties • Addresses largely untapped market of 41 million Americans • Proven commercial strategy to increase prescriptions and capitalize on insurance reimbursement to drive revenues

NovaBay Pharmaceuticals — Investor Presentation (June 2017) on 6ix